WP
VYGR icon

Woodline Partners’s Voyager Therapeutics VYGR Stock Holding History

Woodline Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$749K Buy
+193,984
New +$764K ﹤0.01% 914
2024
Q3 		– Sell
-300,000
Closed -$2.37M – 714
2024
Q2 		$2.37M Hold
300,000
– – 0.02% 408
2024
Q1 		$2.79M Buy
+300,000
New +$2.53M 0.03% 410

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Woodline Partners's VYGR Position: Q1 2026 in Review

Woodline Partners opened a new position in Voyager Therapeutics (VYGR) in Q1 2026: 193,984 shares worth $749K. The stake represents ﹤0.01% of the portfolio and ranks #914 among its holdings. This is a return to the name: Woodline Partners previously reported a position in VYGR as recently as Q2 2024.

Woodline Partners first reported a position in VYGR in Q1 2024 and has held it in 3 quarters since. The position peaked at $2.79M in Q1 2024. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Woodline Partners held 193,984 shares of Voyager Therapeutics worth $749K as of Q1 2026.
  • Voyager Therapeutics was a new Woodline Partners position in Q1 2026.
  • Voyager Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q1 2026, its #914 holding.
  • Woodline Partners first reported a position in Voyager Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Woodline Partners's Voyager Therapeutics position peaked at $2.79M in Q1 2024.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.